T1	Drug 50 74	Systemic corticosteroids
T2	Temporal 96 123	within 7 days of first dose
T3	Drug 127 131	852A
T4	Drug 133 140;152 160	topical steroids
T5	Drug 144 160	inhaled steroids
*	OR T4 T5
R1	Has_temporal Arg1:T1 Arg2:T2	
R2	AND Arg1:T2 Arg2:T3	
T6	Scope 133 172	topical or inhaled steroids are allowed
T7	Drug 175 203	Investigational drugs/agents
T8	Temporal 204 232	within 14 days of first dose
T9	Drug 236 240	852A
R4	AND Arg1:T8 Arg2:T9	
R5	Has_temporal Arg1:T7 Arg2:T8	
T10	Procedure 242 267	Immunosuppressive therapy
T11	Drug 279 295	cytotoxic agents
R6	Subsumes Arg1:T10 Arg2:T11	
T12	Temporal 296 324	within 14 days of first dose
T13	Drug 328 332	852A
R7	AND Arg1:T12 Arg2:T13	
R8	Has_temporal Arg1:T10 Arg2:T12	
T14	Drug 334 346	nitrosoureas
T15	Temporal 347 375	within 30 days of first dose
R9	Has_temporal Arg1:T14 Arg2:T15	
*	OR T10 T14
T16	Drug 378 424	Drugs known to induce QT interval prolongation
T17	Drug 378 392;432 458	Drugs known to induce Torsades de pointes
T19	Scope 378 458	Drugs known to induce QT interval prolongation and/or induce Torsades de pointes
T20	Procedure 533 545	Radiotherapy
T21	Temporal 546 578	within 3 weeks of the first dose
T22	Drug 582 586	852A
R11	AND Arg1:T21 Arg2:T22	
R12	Has_temporal Arg1:T20 Arg2:T21	
T23	Procedure 588 622	Hematopoietic cell transplantation
T24	Temporal 623 651	within 4 weeks of first dose
T25	Drug 655 659	852A
R13	AND Arg1:T24 Arg2:T25	
R14	Has_temporal Arg1:T23 Arg2:T24	
T26	Condition 673 689	active infection
T27	Observation 661 669	Evidence
R15	AND Arg1:T27 Arg2:T26	
T28	Temporal 690 717	within 3 days of first dose
T29	Drug 721 725	852A
R16	AND Arg1:T28 Arg2:T29	
R17	Has_temporal Arg1:T27 Arg2:T28	
T30	Condition 734 750	fungal infection
T31	Condition 754 775	pulmonary infiltrates
*	OR T30 T31
T32	Condition 777 798	prior treated disease
T33	Qualifier 799 805	stable
R18	Has_qualifier Arg1:T32 Arg2:T33	
T34	Temporal 806 817	for 2 weeks
R19	Has_temporal Arg1:T33 Arg2:T34	
T35	Scope 734 775	fungal infection or pulmonary infiltrates
T36	Condition 833 849	Cardiac ischemia
T37	Condition 851 870	cardiac arrhythmias
T38	Condition 874 898	congestive heart failure
*	OR T37 T36 T38
T39	Qualifier 899 925	uncontrolled by medication
R21	Has_qualifier Arg1:T38 Arg2:T39	
T40	Observation 927 934	History
T41	Observation 942 959	clinical evidence
T42	Condition 1019 1091;964 981	could confound the results of the study or put the subject at undue risk a condition which
*	OR T40 T41
T43	Scope 927 962	History of, or clinical evidence of
R22	AND Arg1:T43 Arg2:T42	
T44	Condition 1106 1118;1130 1137	intercurrent illness
T45	Condition 1122 1137	chronic illness
*	OR T44 T45
T46	Qualifier 1093 1105	Uncontrolled
T47	Condition 1146 1164	autoimmune disease
T48	Qualifier 1165 1174	requiring
T49	Procedure 1175 1200	immunosuppressive therapy
T50	Temporal 1201 1215	within 30 days
R23	AND Arg1:T48 Arg2:T49	
R24	Has_temporal Arg1:T48 Arg2:T50	
*	OR T47 T48
T51	Condition 1224 1244	coagulation disorder
T52	Temporal 1139 1145	Active
R25	Has_temporal Arg1:T47 Arg2:T52	
T53	Temporal 1217 1223	Active
R26	Has_temporal Arg1:T51 Arg2:T53	
T54	Qualifier 1249 1275	controlled with medication
T55	Negation 1245 1248	not
R27	Has_negation Arg1:T54 Arg2:T55	
R28	Has_qualifier Arg1:T51 Arg2:T54	
T56	Condition 1277 1285	Pregnant
T57	Condition 1289 1298	lactating
*	OR T56 T57
T58	Condition 1311 1321	malignancy
T59	Temporal 1300 1310	Concurrent
R29	Has_temporal Arg1:T58 Arg2:T59	
T60	Value 1340 1356	at least 5 years
T61	Qualifier 1357 1369	disease free
R30	Has_value Arg1:T61 Arg2:T60	
T62	Qualifier 1326 1338	in remission
A1	Optional T62
R31	Has_qualifier Arg1:T62 Arg2:T61	
R32	Has_qualifier Arg1:T58 Arg2:T62	
T63	Condition 1382 1409	localized (in-situ) disease
T64	Condition 1411 1427	basal carcinomas
T65	Condition 1432 1466	cutaneous squamous cell carcinomas
T66	Qualifier 1482 1500	adequately treated
*	OR T63 T64 T65
T67	Scope 1382 1466	localized (in-situ) disease, basal carcinomas and cutaneous squamous cell carcinomas
R33	Has_qualifier Arg1:T67 Arg2:T66	
T68	Condition 1517 1533	brain metastases
T69	Observation 1506 1516	history of
T70	Condition 1537 1546;1554 1590	any other central nervous system (CNS) disease
T71	Temporal 1547 1553	active
R35	Has_temporal Arg1:T70 Arg2:T71	
*	OR T68 T70
T72	Scope 1517 1590	brain metastases or any other active central nervous system (CNS) disease
R36	Has_scope Arg1:T69 Arg2:T72	
T73	Negation 818 830	is allowable
R20	Has_negation Arg1:T32 Arg2:T73	
T74	Scope 777 830	prior treated disease stable for 2 weeks is allowable
R37	Has_scope Arg1:T35 Arg2:T74	
T75	Negation 1371 1381	except for
T76	Scope 1382 1500	localized (in-situ) disease, basal carcinomas and cutaneous squamous cell carcinomas that have been adequately treated
R34	Has_negation Arg1:T76 Arg2:T75	
R38	Has_scope Arg1:T58 Arg2:T76	
T77	Negation 161 172	are allowed
T78	Scope 133 160	topical or inhaled steroids
R3	Has_negation Arg1:T78 Arg2:T77	
R39	Has_scope Arg1:T1 Arg2:T6	
T18	Non-representable 459 531	unless best available drug required to treat life-threatening conditions
T83	Qualifier 84 94	injectable
T84	Qualifier 76 80	oral
*	OR T83 T84
T85	Scope 76 94	oral or injectable
R40	Has_scope Arg1:T1 Arg2:T85	
